chronic myeloid leukemia immunotherapy in patients undergoing reduced intensity allografts for Post-transplant imatinib as a strategy to postpone the requirement for
暂无分享,去创建一个
C. Craddock | K. Piper | J. Byrne | J. Goldman | M. Griffiths | J. Perz | S. Avery | D. O’Shea | A. Lennard | L. Pallan | J. Arrazi